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Volume 57, Number 1 Letters to the Editor 301Regarding “Impact of screening versus symptomatic
measurement of deep vein thrombosis in a national
quality improvement registry”
This important study demonstrates that if one looks for partic-
ular problems, one will ﬁnd them much more often than if one
does not look for them.1 De Martino et al compared the National
Surgical Quality Improvement Program (NSQIP) database to
a predeﬁned literature search, evaluating deep vein thrombosis
(DVT) identiﬁed by symptomatic status or surveillance status. Of
interest, the rate of DVT in NSQIP was essentially equivalent to
the rate of symptomatic DVTs, whereas the rate in surveillance
studies was much higher, ranging from 2.6-fold higher for gastric
bypass to 14.5-fold higher for hip arthroplasty procedures. The
only procedure where this relationship did not hold was for ampu-
tations, where the rate in NSQIP was much lower than both symp-
tomatic and surveillance cohorts.
A major theme underlying the ﬁndings of this study is that
DVT measures may be too “noisy” to serve as reliable hospital-
quality indicators. Hospital-speciﬁc DVT rates are likely to be
confounded by variation in the inclusion of upper extremity
DVTs, uncertainty about when superﬁcial phlebitis and infrapopli-
teal DVTs “count,” and varying thresholds for what needs to be
“treated.” As highlighted by the authors, variation in the adoption
of aggressive duplex screening programs in asymptomatic patients
could confound DVT rates. Subtler variation in how readily hospi-
tals obtain duplex scans for gray-area indications—fever workups,
mild hypoxemia, borderline symptoms—may be an even more
important source of measurement bias.
The ﬁndings of this study come as ACS-NSQIP is being
increasingly adopted to assess surgical quality. Depending on
how DVT is deﬁned, an institution with an aggressive screening
protocol may be labeled as a lower-quality facility due to a higher
rate of DVT than one that only counts symptomatic DVT or uses
the American College of Surgeons (ACS)-NSQIP for determining
rates of DVT. ACS-NSQIP is an important and broadly visible
national quality-improvement program. As the results of ACS-
NSQIP are often widely studied and quoted, it is important that
when comparing ones’ own data to ACS-NSQIP, deﬁnitions
need to be standardized so that proper comparisons can be
made. Only then can quality be truly improved.
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Reply
We would like to thank Drs Wakeﬁeld and Birkmeyer for their
insightful comments regarding our article. Their editorial empha-
sizes the prominent role that the American College of Surgeons-
National Surgical Quality Improvement Program (ACS-NSQIP)
plays nationally in quality improvement. Further, they highlight
the myriad of ways in which a hospital’s deep vein thrombosis
(DVT) rates can be confounded by the manner in which one looks
for, and measures, this important complication.
We suspect that most practicing surgeons are acutely aware
that if one looks hard enough for trouble, you’re likely to ﬁnd it.
Venous thromboembolism (VTE) events remain potentially
preventable, thus an identiﬁable target for quality improvement
and measurement. But, measuring results and improving quality
requires that everyone “looks” for complications, and records
their results, in the same manner. We agree with the group from
Michigan-who are national leaders in VTE detection, measure-
ment, and prevention,1-3 that ACS-NSQIP needs standardized
deﬁnitions to describe the manner is which the DVT was
detected (symptomatic versus surveillance). Then, centers can
understand their results in a meaningful manner to identify areas
for improvement.
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